Sanolla Revenue

About Sanolla

Founded in 2016, Sanolla aims to transform how healthcare professionals diagnose and monitor patients. Our mission is to enhance primary care by empowering clinicians with smarter, more precise diagnostic tools that improve outcomes. The company is a world leader in developing AI-based infrasound auscultation technology, a breakthrough innovation that captures and analyzes the full spectrum of body sounds, including frequencies below the threshold of human hearing. This previously untapped layer of clinical data opens new possibilities in early disease detection, accurate assessments, and better patient care. The AI algorithm was developed using over 100,000 human body auscultation recordings collected from clinical institutions across the EU and the US. These recordings cover a wide range of medical indications, including cardiology, pulmonology, and others. Sanolla is the first, and currently the only, company to assemble such a comprehensive database, enabling the development of highly reliable and sophisticated diagnostic analysis. Sanolla’s cutting-edge technology has already shown promise in clinical settings, offering a dramatic improvement in diagnostic capabilities for heart and lung conditions. Sanolla is targeting two key market segments: - Enhancing Point-of-Care Assessments: Sanolla’s VoqX - The AI-powered digital stethoscope revolutionizes real-time patient evaluation by caregivers. Unlike the traditional acoustic stethoscope, largely unchanged for over 200 years, Sanolla’s device is designed for the technologies and demands of the 21st century, providing advanced diagnostic insights at the point of care. - Home Monitoring for Chronic Patients (CHF, COPD) - For patients with chronic conditions such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD), Sanolla offers early detection of clinical deterioration, helping to prevent unnecessary ER visits and hospitalizations.

View contact profiles from Sanolla